Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.
This corporate disclosure from STELLA PHARMA CORPORATION was processed by Pulse News Wire on June 22, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Jun 22 (Pulse News Wire) – STELLA PHARMA CORPORATION (4888) announced a third-party allotment of stock warrants. KEY TERMS: - Warrants to be issued: 10,500 - Shares per warrant: 100 - Maximum
View all STELLA PHARMA CORPORATION disclosures →
STELLA PHARMA CORPORATION [4888.T]
TOKYO, Jun 22 (Pulse News Wire) – STELLA PHARMA CORPORATION (4888) announced a third-party allotment of stock warrants.
KEY TERMS: - Warrants to be issued: 10,500 - Shares per warrant: 100 - Maximum dilution: 1,050,000 shares - Gross proceeds: ¥316 million - Allocation date: 2026-06-22
🟢 Confidence: High AI-translated content.